Stomach cancer
Drug research and approvals for stomach cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 737 studies of stomach cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 737
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction…NCT07933471 · Phase 2 · Beijing Tsinghua Chang Gung Hospital · starts Aug 5, 2026
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsNCT07923214 · Phase 1 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · starts Jul 2, 2024
- Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or…NCT07920224 · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jul 19, 2025
- Epinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal DissectionNCT07920068 · Not applicable · Unidade Local de Saúde do Alto Ave, EPE · starts Jul 30, 2025
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisNCT07914764 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Aug 1, 2026
- A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted ImmunochemotherapyNCT07911280 · Phase 2 · Samsung Medical Center · starts Oct 6, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Development and Utilization of an Integrated Clinical Genomic DatabaseNCT07911267 · Not reported · Samsung Medical Center · starts Dec 6, 2024
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.NCT07903415 · Phase 1 · Pfizer · starts Nov 5, 2026
Approved 5
- CapecitabineThymidylate synthase inhibitor
- DocetaxelTubulin inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- TislelizumabProgrammed cell death protein 1 inhibitor
- RamucirumabVascular endothelial growth factor receptor 2 inhibitor
Phase 3 12 of 59
- OxaliplatinDNA inhibitor
- TegafurRNA inhibitor
- GimeracilDihydropyrimidine dehydrogenase inhibitor
- Oteracil
- CisplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- FluorouracilThymidylate synthase inhibitor
- Leucovorin
- IrinotecanDNA topoisomerase I inhibitor
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
- SintilimabProgrammed cell death protein 1 antagonist
Phase 2 12 of 107
- ToripalimabProgrammed cell death protein 1 antagonist
- FloxuridineThymidylate synthase inhibitor
- Disitamab vedotinReceptor tyrosine-protein kinase erbB-2 binding agent
- CarboplatinDNA inhibitor
- LenvatinibVascular endothelial growth factor receptor inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- SavolitinibHepatocyte growth factor receptor inhibitor
- CadonilimabProgrammed cell death protein 1 inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- LapatinibReceptor protein-tyrosine kinase erbB-2 inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
Phase 1 or earlier 12 of 52
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- Penicillin gBacterial penicillin-binding protein inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- GolvatinibHepatocyte growth factor receptor inhibitor
- LMB-9Lewis Y antigen binding agent
- MitoxantroneDNA topoisomerase II alpha inhibitor
- BleomycinDNA inhibitor
- Sacituzumab govitecanTumor-associated calcium signal transducer 2 binding agent
- UmbralisibPI3-kinase p110-delta subunit inhibitor
- LinagliptinDipeptidyl peptidase IV inhibitor
- TrametinibDual specificity mitogen-activated protein kinase kinase 2 inhibitor
- AxitinibVascular endothelial growth factor receptor inhibitor
How its trials ended
2,355 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 371 whose ending is known, 38% met their primary endpoint, 12% missed it and 50% stopped early.
- Completed, result not reported69630%
- Ongoing66928%
- Status unknown61926%
- Met its primary endpoint1406%
- Stopped: other or unclear874%
- Stopped: enrollment or feasibility472%
- Missed its primary endpoint462%
- Stopped: sponsor or business decision281%
- Stopped: lack of efficacy161%
- Stopped: safety6<1%
- Stopped: funding1<1%
| Dec 10, 2025 | 7-ethtyl-10-hydroxycamptothecin and irinotecanTreatment of stomach cancer (including gastroesophageal junction cancer) | SN BioScience Inc. | Designated |
| May 29, 2007 | PlevitrexedTreatment of gastric (stomach cancer | BTG International Ltd | Designated |
| Dec 10, 2004 | 20-mer complementary to Akt mRNATreatment of stomach cancer | Rexahn Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA